<![CDATA[Novo Nordisk A/S - Stock Exchange Announcements]]><![CDATA[Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2012]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

 Company Announcement no 10 / 2012   

]]><![CDATA[Novo Nordisk files annual report with the SEC]]>Novo Nordisk A/S has filed its Annual Report 2011 on Form 20-F for the financial year 2011 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2011. The reports are available at the SEC's website, www.sec.gov as well as at novonordisk.com - Investors - Download centre (listed under 2011).

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at  (...)

]]><![CDATA[Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 3 February 2012]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Company Announcement no 9 / 2012

]]><![CDATA[Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 2 February 2012]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Company Announcement no 8 / 2012

]]><![CDATA[Novo Nordisk increased operating profit by 18% in 2011]]>Sales growth of 9% driven by Victoza®, NovoRapid® and Levemir®

  • Sales increased by 11% in local currencies and by 9% in Danish kroner.
    • Sales of modern insulins increased by 11% (8% in Danish kroner).
    • Victoza® sales of DKK 5,991 million (growth of 159% in Danish kroner).
    • Sales of NovoSeven® increased by 7% (4% in Danish kroner).
    • Sales in North America increased by 18% (13% in Danish kroner).
    • Sales in International Operations increased by 17% (12% in Danish kroner).
  • Gross margin improved by  (...)
]]><![CDATA[Novo Nordisk A/S: Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 6 / 2012

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information: 

Company Announcment no 5 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 

 Company Announcement no 4 / 2012      

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 3 / 2012     

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 2 / 2012

]]><![CDATA[Novo Nordisk A/S : Status regarding Novo Nordisk's holding of its own shares (31 December 2011)]]>In continuation of the company's announcement dated 2 November 2011 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2011 owned 24,440,186 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 24,440,186 or 4.21% of the total share capital.

 (...)]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:


Company Announcement no 81 / 2011

]]><![CDATA[Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan]]>Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes.

Further information:

Company Announcement no 80 / 2011

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:


Company Announcement no 79 / 2011

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 78 / 2011

]]><![CDATA[Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 7 December 2011 and on 8 December 2011]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in and transfers of Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Company Announcement no 77  (...)

]]><![CDATA[Novo Nordisk A/S: Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 Company Announcement no 76 / 2011

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:


Company Announcement no 75 / 2011

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 74 / 2011 

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.


Company Announcement no 73 / 2011

]]>